SWTX250117P25000
- 0.37
- +0.12+48.00%
SpringWorks Therapeutics Newsroom
SpringWorks Therapeutics Price Target Cut to $78.00/Share From $80.00 by Guggenheim
SpringWorks Therapeutics Analyst Ratings
Guggenheim Initiates SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $78
BofA Securities Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Cuts Target Price to $55
Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Springworks Therapeutics (SWTX)
Barclays Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
J.P. Morgan Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group
SpringWorks Therapeutics Analyst Ratings
Evercore Initiates SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $60
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $58 to $74
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
Buy Rating Reaffirmed for Springworks Therapeutics Amid Promising Outlook for Ogsiveo and Mirdametinib
SpringWorks Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Springworks Therapeutics: Strong Cash Position and Promising Drug Approval Outlook Justify Buy Rating
TD Cowen Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Maintains Target Price $63
TD Cowen Remains a Buy on Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Is Maintained at Overweight by JP Morgan
J.P. Morgan Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating, Raises Target Price to $68
Goldman Sachs Maintains SpringWorks Therapeutics(SWTX.US) With Buy Rating